Research, development, production and distribution of nutritional health supplements,
dermocosmetics, dietary foods for special medical purposes and medical devices
<a href="/events">We will be present </a>
<a href="/about-us/quality">Certified quality</a>

Amnol is committed to maintaining the quality of its products and manufacturing processes, proven by n.6860A ISO 9001:2008 certification. The company guarantees excellence in its nutritional health supplements, dermocosmetics and medical devices by means of scrupulous methods of control and state of the art instruments, thus safeguarding the well-being of end-users.

<a href="/expert">Ask the expert</a>

Our experts are at your disposal for any enquiries you may have regarding Amnol's products and will respond to your requests for any further information or informative literature. Please contact them by email or call on our toll free number.

News from the world

News from the world

  • The short-term efficacy of vena cava filters for t...
    CONCLUSIONS: Inferior vena cava filter in addition to anticoagulation was not associated with a reduction in the incidence of recu...
  • A systematic review of clinical prediction scores ...
    CONCLUSION: Detailed knowledge of the development of the various clinical prediction scores for deep vein thrombosis is essential ...
  • Response to letter: Long-term follow-up results of...
    Authors: Whiteley M, Dos Santos S PMID: 27864562 [PubMed - as supplied by publisher] (Source: Phlebology)
  • What is pathological May-Thurner syndrome?
    Authors: Hameed M, Onida S, Davies AH PMID: 27864560 [PubMed - as supplied by publisher] (Source: Phlebology)
  • Incidence of deep vein thrombosis in patients unde...
    CONCLUSIONS: The morbidity of deep vein thrombosis in patients who underwent breast reconstruction using autologous tissue transfe...
  • Impact of UK NICE Clinical Guidelines 168 and soci...
    CONCLUSIONS: CG168 has increased VV interventions as well as the number referred with LU. However, this improvement in access to t...
  • A standardized ultrasound approach to pelvic conge...
    Authors: Labropoulos N, Jasinski PT, Adrahtas D, Gasparis AP, Meissner MH Abstract Pelvic congestion syndrome is one of th...
  • The predictive value of haemodynamic parameters fo...
    CONCLUSIONS: Data on the predictive value of haemodynamic parameters for success of treatment in deep venous obstructive disease a...
  • Short-term results of isolated phlebectomy with pr...
    CONCLUSION: Isolated phlebectomy with a preservation of incompetent great saphenous vein leads to disappearance of reflux in a maj...
  • A specifically designed aquatic exercise protocol ...
    CONCLUSION: A specifically designed aquatic protocol is able to positively impact chronic leg swelling offering a first line rehab...
Newsletter

Newsletter

Sign up to our newsletter to keep up-to-date about what's new at AMNOL.








AMNOL Chimica Biologica S.r.l.
Registered office, Administrative and Sales Offices: Corso della Vittoria 14, 28100 Novara
Tel: +39 0321 499199 - Email: info@amnol.net
Share Capital € 250,000 issued capital R.E.A. Novara 10937 VAT code 01228730030 Tax Code 04170400156



AMNOL Chimica Biologica and Euronational are companies of the WTB group (company subject to management and co-ordination activity pursuant to Art.2497 CC by WTB Holding S.p.A. - Milan)


Quality Management System Certified by KIWA CERMET according to the UNI EN ISO 9001:2008 Reg No. 6860-A.

Copyright 2016 by Amnol Chimica Biologica